Chenodeoxycholic Acid Powder, identified by the CAS number 474-25-9, stands as a pivotal pharmaceutical raw material globally. This high-purity substance, typically presenting as a fine white crystalline powder, is a primary bile acid synthesized in the liver from cholesterol. Its significance in both natural metabolic processes and therapeutic applications makes it an indispensable compound in the pharmaceutical industry.

As a bile acid, Chenodeoxycholic Acid plays a crucial role in the digestive system, primarily aiding in the emulsification and absorption of fats and fat-soluble vitamins in the small intestine. However, its utility extends far beyond basic digestion, forming the basis for several important medical treatments.

The physical characteristics of Chenodeoxycholic Acid Powder are critical for its application and handling. It is characterized by a melting point typically ranging between 165°C and 171°C. While practically insoluble in water, it exhibits solubility in organic solvents such as alcohol and acetic acid. This solubility profile is important for formulation development in pharmaceutical manufacturing processes. The high purity of 99% or greater is a standard requirement, ensured through rigorous analytical testing methods such as High-Performance Liquid Chromatography (HPLC).

One of the most well-established medical uses of Chenodeoxycholic Acid is in the treatment of cholesterol gallstones. Oral administration of this compound can help to dissolve gallstones by decreasing the cholesterol saturation index of bile. This mechanism involves suppressing hepatic cholesterol synthesis and promoting bile acid synthesis, thereby altering the composition of bile to favor cholesterol dissolution. This therapy offered a non-surgical alternative for patients with certain types of gallstones, particularly those that are cholesterol-rich and radiolucent.

Beyond gallstone therapy, Chenodeoxycholic Acid is also a cornerstone treatment for a rare genetic lipid storage disorder known as Cerebrotendineous Xanthomatosis (CTX). CTX is characterized by impaired bile acid synthesis, leading to the accumulation of cholesterol and cholestanol in various tissues, including the brain, tendons, and eyes. Chenodeoxycholic Acid replacement therapy effectively reduces the production and accumulation of these abnormal sterols, significantly improving neurological symptoms and preventing disease progression in affected individuals. This application highlights the compound's role in correcting metabolic defects.

Furthermore, Chenodeoxycholic Acid has been explored and used in combination therapies for other conditions, including certain regimens for managing Hepatitis C infections. While direct-acting antiviral agents have revolutionized Hepatitis C treatment, the historical and ongoing research into adjunctive therapies involving bile acids like chenodeoxycholic acid underscores its multifaceted biological activity and potential therapeutic scope.

Sourcing high-quality Chenodeoxycholic Acid Powder is paramount for pharmaceutical manufacturers. The purity, physical form, and consistency of the material directly impact the efficacy and safety of the final drug product. Manufacturers must adhere to stringent quality control standards throughout the production process, from raw material sourcing to final purification and packaging. Comprehensive documentation, including Certificates of Analysis (COA), Material Safety Data Sheets (MSDS), and certifications such as ISO, KOSHER, Halal, and SGS, are essential to ensure compliance with global regulatory requirements and guarantee the product's quality and suitability for pharmaceutical use.

Reliable suppliers maintain significant production capacity and ensure proper storage conditions, typically in a cool, dry place, to preserve the stability and shelf life of the powder, which is generally two years under recommended conditions. The ability to provide samples and support customized orders further facilitates development and production for pharmaceutical clients.

The global demand for high-purity pharmaceutical APIs like Chenodeoxycholic Acid necessitates a robust and dependable supply chain. Choosing a supplier with a proven track record in quality, consistency, and regulatory compliance is critical for uninterrupted production and market supply of essential medicines. The availability of technical support and detailed product information ensures that manufacturers can integrate this raw material seamlessly into their processes.

For pharmaceutical companies and researchers looking to procure this essential API, understanding the nuances of the supply market is vital. Finding a reputable manufacturer and supplier that can provide consistent quality Chenodeoxycholic Acid Powder is key. Information regarding the current market price, minimum order quantities, and efficient logistics for delivery are crucial considerations for procurement teams. Learning how to effectively buy or purchase this specialized raw material involves evaluating supplier capabilities, verifying product specifications, and establishing reliable long-term partnerships to meet ongoing production needs. Reliable sourcing ensures the continuous availability of treatments for gallstones, CTX, and other medical conditions where Chenodeoxycholic Acid is indicated.